Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India (SPOTLIGHT)
Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India (SPOTLIGHT)
Sponsor: Novartis Pharmaceuticals
Terminated
sponsor decision
Other terminated trials from Novartis Pharmaceuticals
Other Sickle Cell Disease trials with similar outcome
A observational or N/A phase clinical study on Sickle Cell Disease, this trial is terminated or withdrawn. The trial is conducted by Novartis Pharmaceuticals and has accumulated 12 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Sep 2024 — Sep 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Feb 2024 — Jul 2024 [monthly]
Terminated
Status: Recruiting → Terminated
-
Sep 2023 — Feb 2024 [monthly]
Recruiting
▶ Show 7 earlier versions
-
Feb 2023 — Sep 2023 [monthly]
Recruiting
-
Nov 2022 — Feb 2023 [monthly]
Recruiting
-
Jul 2022 — Nov 2022 [monthly]
Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Recruiting
-
Dec 2021 — Jun 2022 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Oct 2021 — Dec 2021 [monthly]
Not Yet Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .